UNSPSC 51363000: Hypnotic thiazoles and thioxanthenes and urea analogs

This classification denotes Hypnotic drugs made from or based in part on thiazoles, thioxanthenes, or urea analogs

UNSPSC 51363000 Hypnotic thiazoles and thioxanthenes and urea analogs is a Class code that encompasses pharmaceutical products, though recent state and local solicitations under this code focus primarily on naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers and direct-to-manufacturer channels. State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida, and the Texas Health and Human Services Commission represent the jurisdictional mix, along with cooperative purchasing vehicles such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which aggregates demand across multiple state and local governments.

Recent activity spans Florida, Texas, and Minnesota-Oregon cooperative purchasing. Seminole County released IFB60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs and therapeutic pharmacy initiatives for self-insured health plans. The Minnesota Department of Administration's MMCAP issued an RFP (S1070000015802) posted January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with contract awards effective July 1, 2026. Vendors must comply with cGMP, the Drug Supply Chain Security Act, E-Verify requirements, and carry commercial general liability insurance of $2,000,000 to $5,000,000 depending on the solicitation.